Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer

Barbara Adamo; Giuseppina Rosaria Rita Ricciardi; Antonio Ieni; Tindara Franchina; Carmine Fazzari; Maria Vita Sanò; Giuseppe Angelico; Michele Caruso; Giovanni Tuccari; Vincenzo Adamo

doi:10.18632/oncotarget.26650

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer

PDF | How to cite

Oncotarget. 2019; 10:917-917. https://doi.org/10.18632/oncotarget.26650

Metrics: PDF 3351 views | ?

Barbara Adamo^1,*, Giuseppina Rosaria Rita Ricciardi^2,*, Antonio Ieni³, Tindara Franchina², Carmine Fazzari⁴, Maria Vita Sanò⁵, Giuseppe Angelico⁶, Michele Caruso⁵, Giovanni Tuccari³ and Vincenzo Adamo²

¹ Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
² Medical Oncology Unit A.O. Papardo & Department of Human Pathology University of Messina, Messina, Italy
³ Department of Human Pathology of Adult and Evolutive Age “Gaetano Barresi”, Section of Pathology, University of Messina, AOU Policlinico ”G. Martino“ Messina, Italy
⁴ Pathology Unit, Humanitas Center of Oncology, Catania, Italy
⁵ Medical Oncology, Humanitas Catania Oncology Center, Catania, Italy
⁶ G. F. Ingrassia Department, Section of Anatomic Pathology, University Hospital “Policlinico-Vittorio Emanuele”, Catania, Italy
^* These authors have contributed equally to this work

Published: January 25, 2019

This article has been corrected: The correct author name and author contributed information is given below:

^* These authors have contributed equally to this work

Original article: Oncotarget. 2017; 8:76974-76986. DOI: https://doi.org/10.18632/oncotarget.20293.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26650

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer